Medesthetics

OCT 2017

MedEsthetics—business education for medical practitioners—provides the latest noninvasive cosmetic procedures, treatment trends, product and equipment reviews, legal issues and medical aesthetics industry news.

Issue link: http://medesthetics.epubxp.com/i/877295

Contents of this Issue

Navigation

Page 62 of 68

60 OCTOBER 2017 | Med Esthetics ALLERGAN ACQUIRES REGENICA STEM CELL TECHNOLOGY Allergan has acquired the Regenica growth factor-based skincare line, and will market the line's proprietary multi- potent cell-conditioned media, which was developed by regenerative medicine company Histogen. Allergan plans to incorporate the technology, known as Multipotent Resignaling Complex (MRCx), in future products under the SkinMedica portfolio. MRCx is made up of soluble cell-sig- naling proteins and growth factors that support the body's epidermal stem cells. "In addition to the Regenica product line, we are look- ing forward to collaborating with Histogen and leveraging their science to further bolster SkinMedica's commitment to evidence-based skincare," said Rahul Mehta, PhD, vice president of research and development at SkinMedica, an Allergan Company. SEBACIA RECEIVES FINANCING TO ADVANCE ACNE MICROPARTICLE TREATMENT Sebacia announced that it has completed a $20 million Se- ries D fi nancing to complete a U.S. pivotal trial of its propri- etary microparticle treatment for moderate to severe acne. The company's gold and silica microparticles—designed to be activated by the light from commonly used hair removal lasers—are placed in a suspension designed to penetrate the sebaceous follicles. When exposed to a laser pulse, they create a focused photothermal effect in the sebaceous gland and follicle to reduce the activity level of the gland and the infl ammatory lesions that cause acne. With the new funding, Sebacia intends to complete the U.S. pivotal trial with expected results reporting by mid- 2018, and submission and FDA response expected by the end of 2018. BONTI RELEASES CLINICAL DATA ON NEW BOTULINUM TOXIN PRODUCT Bonti, a clinical-stage biotechnology company, has an- nounced topline results of the fi rst clinical study of its lead product candidate, EB-001, in glabellar lines. EB-001 is a novel serotype E botulinum neurotoxin with a unique effi cacy profi le, characterized by fast onset of action (about 24 hours) and short duration of effect (about 4 weeks). The study achieved its objectives and confi rmed both favorable safety and the expected clinical effi cacy profi le. Key fi ndings of effi cacy results included: EB-001 demonstrated dose-dependent clinical activity and effi cacy at multiple dos- es. At the high dose cohorts, a 2-point response (assessed by the investigator) was observed within 24 hours of injection. At the two high doses, a 2-point response was reported in 80% of EB- 001 subjects and in 14% of the placebo group. The duration of clinical effect was two to four weeks post- injection in the high dose groups. The randomized, double-blind, placebo-controlled, ascending dose cohort study enrolled 42 toxin-naive adults with moderate to severe glabellar (frown) lines. Each subject received a single treatment cycle comprising fi ve injection sites in the forehead glabellar muscles. All doses evaluated in the study were well tolerated and there were no serious adverse events (AEs) or discon- tinuation due to AEs. The overall incidence of treatment- emergent AEs was 0% in the placebo group and 14% of EB-001 subjects. AEs included headache, sore throat and fl u-like symptoms, and were transient and mild or moderate in severity. VALEANT DERMATOLOGY NOW ORTHO DERMATOLOGICS Valeant is rebranding its dermatolo- gy products under the name Ortho Dermatologics, which was acquired by Valeant in 2011. The rebranding coincides with the company's launch of SILIQ, a biologic drug approved for the treatment of psoriasis. "The branding under Ortho Dermatolog- ics allows us to showcase what we have as a company," says William (Bill) Humphries, executive vice president of dermatology at Valeant. "We have more than 100 years of dermatology experience on the team now and we have a portfolio of dermatology products that, I think, is unrivaled in the industry." In addition to the launch of SILIQ, the company has nine additional dermatology products currently in development, including IDP-118, a combination halobetasol propionate and tazarotene lotion for the treatment of psoriasis, plus four acne products. The company's existing acne treatments include Retin-A Micro, Solodyn and Onexton. The company's goal with the rebranding is to rebuild trust within the dermatology community by creating a well- respected team and to encourage the connectivity between product developers, physicians and patients for which Ortho was known. "This is an opportunity for dermatologists to re- ally engage with us as we grow this business, and bring new products to them and their patients," says Humphries. SIENTRA ACQUIRES MIRAMAR LABS Medical aesthetics company Sientra has acquired Miramar Labs. The acquisition brings the miraDry system, FDA-cleared to reduce underarm sweat and odor, and permanently reduce hair of all colors, to Sientra's product portfolio. NEWS & EVENTS William Humphries

Articles in this issue

Archives of this issue

view archives of Medesthetics - OCT 2017